Exploring Optimal Parameters for Ligand-Based Virtual Screening in Early Drug Discovery
Abstract
Ligand-based virtual screening depends on choices that are often treated as implementation details, including the similarity threshold, fingerprint setting and atom-invariant scheme. We examined how these choices altered the composition of ranked searches against the Enamine library for four aminergic reference ligands: atomoxetine, bupropion, mirtazapine and venlafaxine. Candidate sets were evaluated by compound-weighted scaffold novelty, normalized Shannon scaffold diversity and three computational estimates of synthetic accessibility. We first identified ligand-specific operating points along cumulative Tanimoto-ranked searches. We then compared five extended-connectivity fingerprint settings at matched retrieval depths and compared ECFP4 with the feature-class analogue FCSFP4. Finally, 240 records, corresponding to 229 unique structures, were scored independently by three chemists who were blinded to the computational scores. No single Tanimoto cutoff described all four searches. ECFP8 provided the most stable pooled setting, although venlafaxine favored ECFP2. ECFP4 was the stronger primary fingerprint in pooled comparisons, whereas FCSFP4 contributed nonredundant chemical space. Agreement among individual chemists was moderate, and the mean rating was more reliable than a single rating. SCScore showed the highest association with the blinded consensus, but performance varied by ligand. These results support a staged screening design in which a pooled default is followed by ligand-specific calibration and expert review.
Related
- Discovery of Novel HDAC8 Inhibitors Through Shape-Based Virtual Screening: Experimental Validation and Characterization of a Promising Quinoline-Based Hit Scaffold
- Large-Scale Prospective Virtual Screening Using a Co-Folding-Rescoring Workflow for NPM1-TYK2 Inhibitor Discovery
- A Proximity-Driven Functional Screening Platform for the Discovery of Noninhibitory USP7 Ligand Enabling Targeted Protein Stabilization
- Virtual Screening–Derived Computational Lead Candidates for MAO-B Inhibition in Parkinson’s Disease: Pathway-Informed Docking, Molecular Dynamics, DFT and ADMET Evaluation
- Adapting Boltz-2 with limited experimental activity data improves early enrichment in virtual screening
BibTeX
@misc{sobodu2026exploring,
title = {{Exploring Optimal Parameters for Ligand-Based Virtual Screening in Early Drug Discovery}},
author = {Temitope Sobodu and Victor Chibuzor Johnson and Ryan Kern and Peter Oni},
howpublished = {arXiv},
year = {2026},
month = sep,
doi = {10.48550/arxiv.2609.16356},
eprint = {2609.16356},
archivePrefix = {arXiv},
url = {https://arxiv.org/abs/2609.16356},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - UNPB
TI - Exploring Optimal Parameters for Ligand-Based Virtual Screening in Early Drug Discovery
AU - Temitope Sobodu
AU - Victor Chibuzor Johnson
AU - Ryan Kern
AU - Peter Oni
PY - 2026
DA - 2026/09/14
PB - arXiv
DO - 10.48550/arxiv.2609.16356
UR - https://arxiv.org/abs/2609.16356
AB - Ligand-based virtual screening depends on choices that are often treated as implementation details, including the similarity threshold, fingerprint setting and atom-invariant scheme. We examined how these choices altered the composition of ranked searches against the Enamine library for four aminergic reference ligands: atomoxetine, bupropion, mirtazapine and venlafaxine. Candidate sets were evaluated by compound-weighted scaffold novelty, normalized Shannon scaffold diversity and three computational estimates of synthetic accessibility. We first identified ligand-specific operating points along cumulative Tanimoto-ranked searches. We then compared five extended-connectivity fingerprint settings at matched retrieval depths and compared ECFP4 with the feature-class analogue FCSFP4. Finally, 240 records, corresponding to 229 unique structures, were scored independently by three chemists who were blinded to the computational scores. No single Tanimoto cutoff described all four searches. ECFP8 provided the most stable pooled setting, although venlafaxine favored ECFP2. ECFP4 was the stronger primary fingerprint in pooled comparisons, whereas FCSFP4 contributed nonredundant chemical space. Agreement among individual chemists was moderate, and the mean rating was more reliable than a single rating. SCScore showed the highest association with the blinded consensus, but performance varied by ligand. These results support a staged screening design in which a pooled default is followed by ligand-specific calibration and expert review.
ER -